Skip to main content
Erschienen in: Diabetologia 1/2016

01.01.2016 | Short Communication

Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries

verfasst von: Jennifer L. Sherr, Julia M. Hermann, Fiona Campbell, Nicole C. Foster, Sabine E. Hofer, Jeremy Allgrove, David M. Maahs, Thomas M. Kapellen, Naomi Holman, William V. Tamborlane, Reinhard W. Holl, Roy W. Beck, Justin T. Warner, for the T1D Exchange Clinic Network, the DPV Initiative, and the National Paediatric Diabetes Audit and the Royal College of Paediatrics and Child Health registries

Erschienen in: Diabetologia | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

While the use of insulin pumps in paediatrics has expanded dramatically, there is still considerable variability among countries in the use of pump technology. The present study sought to describe differences in metabolic control and pump use in young people with type 1 diabetes using data collected in three multicentre registries.

Methods

Data for the years 2011 and 2012 from 54,410 children and adolescents were collected from the Prospective Diabetes Follow-up Registry (DPV; n = 26,198), T1D Exchange (T1DX; n = 13,755) and the National Paediatric Diabetes Audit (NPDA; n = 14,457). The modality of insulin delivery, based on age, sex and ethnic minority status, and the impact of pump use on HbA1c levels were compared.

Results

The overall mean HbA1c level was higher in the NPDA (8.9 ± 1.6% [74 ± 17.5 mmol/mol]) than in the DPV (8.0 ± 1.6% [64 ± 17.0 mmol/mol], p < 0.001) and T1DX (8.3 ± 1.4% [68 ± 15.4 mmol/mol], p < 0.001). Conversely, pump use was much lower in the NPDA (14%) than in the DPV (41%, p < 0.001) and T1DX (47%, p < 0.001). In a pooled analysis, pump use was associated with a lower mean HbA1c (pump: 8.0 ± 1.2% [64 ± 13.3 mmol/mol] vs injection: 8.5 ± 1.7% [69 ± 18.7 mmol/mol], p < 0.001). In all three registries, those with an ethnic minority status were less likely to be treated with a pump (p < 0.001) and boys were treated with a pump less often compared with girls (p < 0.001).

Conclusions/interpretation

Despite similar clinical characteristics and proportion of minority participants, substantial differences in metabolic control exist across the three large transatlantic registries of paediatric patients with type 1 diabetes, which appears to be due in part to the frequency of insulin pump therapy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Tamborlane WV, Sherwin RS, Genel M, Felig P (1979) Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 300:573–578CrossRefPubMed Tamborlane WV, Sherwin RS, Genel M, Felig P (1979) Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 300:573–578CrossRefPubMed
2.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
3.
Zurück zum Zitat Sherr J, Cengiz E, Tamborlane WV (2009) From pumps to prevention: recent advances in the treatment of type 1 diabetes. Drug Discov Today 14:973–981CrossRefPubMed Sherr J, Cengiz E, Tamborlane WV (2009) From pumps to prevention: recent advances in the treatment of type 1 diabetes. Drug Discov Today 14:973–981CrossRefPubMed
4.
Zurück zum Zitat Johnson SR, Cooper MN, Jones TW, Davis EA (2013) Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study. Diabetologia 56:2392–2400CrossRefPubMed Johnson SR, Cooper MN, Jones TW, Davis EA (2013) Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study. Diabetologia 56:2392–2400CrossRefPubMed
5.
Zurück zum Zitat Phillip M, Battelino T, Rodriguez H et al (2007) Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 30:1653–1662CrossRefPubMed Phillip M, Battelino T, Rodriguez H et al (2007) Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 30:1653–1662CrossRefPubMed
6.
Zurück zum Zitat Maahs DM, Hermann JM, Holman N et al (2015) Rates of diabetic ketoacidosis: international comparison with 49,859 pediatric patients with type 1 diabetes from England, Wales, the U.S., Austria, and Germany. Diabetes Care 38:1876–1882CrossRefPubMed Maahs DM, Hermann JM, Holman N et al (2015) Rates of diabetic ketoacidosis: international comparison with 49,859 pediatric patients with type 1 diabetes from England, Wales, the U.S., Austria, and Germany. Diabetes Care 38:1876–1882CrossRefPubMed
7.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group (1994) Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 125:177–188CrossRef The Diabetes Control and Complications Trial Research Group (1994) Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 125:177–188CrossRef
8.
Zurück zum Zitat Rewers MJ, Pillay K, de Beaufort C et al (2014) Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 15(Suppl 20):102–114CrossRefPubMed Rewers MJ, Pillay K, de Beaufort C et al (2014) Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 15(Suppl 20):102–114CrossRefPubMed
9.
Zurück zum Zitat Chiang JL, Kirkman MS, Laffel LM, Peters AL, Type 1 Diabetes Sourcebook Authors (2014) Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 37:2034–2054CrossRefPubMed Chiang JL, Kirkman MS, Laffel LM, Peters AL, Type 1 Diabetes Sourcebook Authors (2014) Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 37:2034–2054CrossRefPubMed
Metadaten
Titel
Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries
verfasst von
Jennifer L. Sherr
Julia M. Hermann
Fiona Campbell
Nicole C. Foster
Sabine E. Hofer
Jeremy Allgrove
David M. Maahs
Thomas M. Kapellen
Naomi Holman
William V. Tamborlane
Reinhard W. Holl
Roy W. Beck
Justin T. Warner
for the T1D Exchange Clinic Network, the DPV Initiative, and the National Paediatric Diabetes Audit and the Royal College of Paediatrics and Child Health registries
Publikationsdatum
01.01.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 1/2016
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3790-6

Weitere Artikel der Ausgabe 1/2016

Diabetologia 1/2016 Zur Ausgabe

Editorial

A new chapter

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.